195 related articles for article (PubMed ID: 32111181)
1. High thromboembolic event rate in patients with locally advanced oesophageal cancer during neoadjuvant therapy. An exploratory analysis of the prospective, randomised intergroup phase III trial SAKK 75/08.
Fehr M; Hawle H; Hayoz S; Thuss-Patience P; Schacher S; Riera Knorrenschild J; Dürr D; Knoefel WT; Rumpold H; Bitzer M; Zweifel M; Samaras P; Mey U; Küng M; Winterhalder R; Eisterer W; Hess V; Gérard MA; Templeton A; Stahl M; Ruhstaller T; ; ; ;
BMC Cancer; 2020 Feb; 20(1):166. PubMed ID: 32111181
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08).
Ruhstaller T; Thuss-Patience P; Hayoz S; Schacher S; Knorrenschild JR; Schnider A; Plasswilm L; Budach W; Eisterer W; Hawle H; Mariette C; Hess V; Mingrone W; Montemurro M; Girschikofsky M; Schmidt SC; Bitzer M; Bedenne L; Brauchli P; Stahl M; ; ; ;
Ann Oncol; 2018 Jun; 29(6):1386-1393. PubMed ID: 29635438
[TBL] [Abstract][Full Text] [Related]
3. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
Al-Batran SE; Hofheinz RD; Pauligk C; Kopp HG; Haag GM; Luley KB; Meiler J; Homann N; Lorenzen S; Schmalenberg H; Probst S; Koenigsmann M; Egger M; Prasnikar N; Caca K; Trojan J; Martens UM; Block A; Fischbach W; Mahlberg R; Clemens M; Illerhaus G; Zirlik K; Behringer DM; Schmiegel W; Pohl M; Heike M; Ronellenfitsch U; Schuler M; Bechstein WO; Königsrainer A; Gaiser T; Schirmacher P; Hozaeel W; Reichart A; Goetze TO; Sievert M; Jäger E; Mönig S; Tannapfel A
Lancet Oncol; 2016 Dec; 17(12):1697-1708. PubMed ID: 27776843
[TBL] [Abstract][Full Text] [Related]
4. Effect of the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation Therapy for Patients With Esophageal Cancer: The NRG Oncology RTOG 0436 Phase 3 Randomized Clinical Trial.
Suntharalingam M; Winter K; Ilson D; Dicker AP; Kachnic L; Konski A; Chakravarthy AB; Anker CJ; Thakrar H; Horiba N; Dubey A; Greenberger JS; Raben A; Giguere J; Roof K; Videtic G; Pollock J; Safran H; Crane CH
JAMA Oncol; 2017 Nov; 3(11):1520-1528. PubMed ID: 28687830
[TBL] [Abstract][Full Text] [Related]
5. Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06).
Ruhstaller T; Pless M; Dietrich D; Kranzbuehler H; von Moos R; Moosmann P; Montemurro M; Schneider PM; Rauch D; Gautschi O; Mingrone W; Widmer L; Inauen R; Brauchli P; Hess V
J Clin Oncol; 2011 Feb; 29(6):626-31. PubMed ID: 21205757
[TBL] [Abstract][Full Text] [Related]
6. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
Al-Batran SE; Homann N; Pauligk C; Goetze TO; Meiler J; Kasper S; Kopp HG; Mayer F; Haag GM; Luley K; Lindig U; Schmiegel W; Pohl M; Stoehlmacher J; Folprecht G; Probst S; Prasnikar N; Fischbach W; Mahlberg R; Trojan J; Koenigsmann M; Martens UM; Thuss-Patience P; Egger M; Block A; Heinemann V; Illerhaus G; Moehler M; Schenk M; Kullmann F; Behringer DM; Heike M; Pink D; Teschendorf C; Löhr C; Bernhard H; Schuch G; Rethwisch V; von Weikersthal LF; Hartmann JT; Kneba M; Daum S; Schulmann K; Weniger J; Belle S; Gaiser T; Oduncu FS; Güntner M; Hozaeel W; Reichart A; Jäger E; Kraus T; Mönig S; Bechstein WO; Schuler M; Schmalenberg H; Hofheinz RD;
Lancet; 2019 May; 393(10184):1948-1957. PubMed ID: 30982686
[TBL] [Abstract][Full Text] [Related]
7. Preoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage IIIB NSCLC: a multicentre phase 2 trial (SAKK 16/08).
Curioni-Fontecedro A; Perentes JY; Gelpke H; Xyrafas A; Bouchaab H; Mach N; Matzinger O; Stojcheva N; Frueh M; Weder W; Cathomas R; Gargiulo P; Bubendorf L; Pless M; Betticher D; Peters S;
Br J Cancer; 2019 May; 120(10):968-974. PubMed ID: 30988393
[TBL] [Abstract][Full Text] [Related]
8. Definitive chemoradiotherapy plus cetuximab for cancer in the oesophagus or gastro-oesophageal junction.
von Döbeln GA; Wagenius G; Holtved E; Jacobsen AB; Nilsson M; Yu J; Baeksgaard L
Cancer Treat Res Commun; 2020; 24():100187. PubMed ID: 32619832
[TBL] [Abstract][Full Text] [Related]
9. Preoperative versus postoperative docetaxel-cisplatin-fluorouracil (TCF) chemotherapy in locally advanced resectable gastric carcinoma: 10-year follow-up of the SAKK 43/99 phase III trial.
Fazio N; Biffi R; Maibach R; Hayoz S; Thierstein S; Brauchli P; Bernhard J; Stupp R; Andreoni B; Renne G; Crosta C; Morant R; Chiappa A; Luca F; Zampino MG; Huber O; Goldhirsch A; de Braud F; Roth AD; ;
Ann Oncol; 2016 Apr; 27(4):668-73. PubMed ID: 26712905
[TBL] [Abstract][Full Text] [Related]
10. Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02).
Ruhstaller T; Widmer L; Schuller JC; Roth A; Hess V; Mingrone W; von Moos R; Borner M; Pestalozzi BC; BalmerMajno S; Köberle D; Terraciano L; Schnider A; Bodis S; Popescu R;
Ann Oncol; 2009 Sep; 20(9):1522-1528. PubMed ID: 19465425
[TBL] [Abstract][Full Text] [Related]
11. A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.
Sanford NN; Catalano PJ; Enzinger PC; King BL; Bueno R; Martin NE; Hong TS; Wo JY; Mamon HJ
Dis Esophagus; 2017 Jul; 30(7):1-8. PubMed ID: 28475728
[TBL] [Abstract][Full Text] [Related]
12. A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma.
Satake H; Tahara M; Mochizuki S; Kato K; Hara H; Yokota T; Kiyota N; Kii T; Chin K; Zenda S; Kojima T; Bando H; Yamazaki T; Iwasa S; Honma Y; Hamauchi S; Tsushima T; Ohtsu A
Cancer Chemother Pharmacol; 2016 Jul; 78(1):91-9. PubMed ID: 27193097
[TBL] [Abstract][Full Text] [Related]
13. The addition of cetuximab to preoperative chemoradiotherapy for locally advanced esophageal squamous cell carcinoma is associated with high rate of long term survival: Mature results from a prospective phase Ib/II trial.
Brenner B; Purim O; Gordon N; Goshen-Lago T; Idelevich E; Kashtan H; Menasherov N; Fenig E; Sulkes A; Kundel Y
Radiother Oncol; 2019 May; 134():74-80. PubMed ID: 31005227
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial.
Cats A; Jansen EPM; van Grieken NCT; Sikorska K; Lind P; Nordsmark M; Meershoek-Klein Kranenbarg E; Boot H; Trip AK; Swellengrebel HAM; van Laarhoven HWM; Putter H; van Sandick JW; van Berge Henegouwen MI; Hartgrink HH; van Tinteren H; van de Velde CJH; Verheij M;
Lancet Oncol; 2018 May; 19(5):616-628. PubMed ID: 29650363
[TBL] [Abstract][Full Text] [Related]
15. Venous thromboembolism during preoperative chemotherapy in the CRITICS gastric cancer trial.
Slagter AE; Sikorska K; Grootscholten C; van Laarhoven HWM; Lind P; Nordsmark M; Meershoek-Klein Kranenbarg E; van de Velde CJH; van Grieken NCT; van Sandick JW; Jansen EPM; Verheij M; Cats A
Cancer Med; 2020 Sep; 9(18):6609-6616. PubMed ID: 32735752
[TBL] [Abstract][Full Text] [Related]
16. Utility of weekly docetaxel combined with preoperative radiotherapy for locally advanced esophageal cancer from pathological analysis.
Kushida T; Nohara S; Yoshino K; Fujiwara D; Ouchi K; Amano T; Isayama F; Tomita N; Iwanuma Y; Sasai K; Tsurumaru M; Kajiyama Y
Dis Esophagus; 2014; 27(4):368-73. PubMed ID: 23865505
[TBL] [Abstract][Full Text] [Related]
17. Health-related quality of life results from the PRODIGE 5/ACCORD 17 randomised trial of FOLFOX versus fluorouracil-cisplatin regimen in oesophageal cancer.
Bascoul-Mollevi C; Gourgou S; Galais MP; Raoul JL; Bouché O; Douillard JY; Adenis A; Etienne PL; Juzyna B; Bedenne L; Conroy T
Eur J Cancer; 2017 Oct; 84():239-249. PubMed ID: 28829992
[TBL] [Abstract][Full Text] [Related]
18. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.
Catenacci DVT; Tebbutt NC; Davidenko I; Murad AM; Al-Batran SE; Ilson DH; Tjulandin S; Gotovkin E; Karaszewska B; Bondarenko I; Tejani MA; Udrea AA; Tehfe M; De Vita F; Turkington C; Tang R; Ang A; Zhang Y; Hoang T; Sidhu R; Cunningham D
Lancet Oncol; 2017 Nov; 18(11):1467-1482. PubMed ID: 28958504
[TBL] [Abstract][Full Text] [Related]
19. Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group.
Starling N; Rao S; Cunningham D; Iveson T; Nicolson M; Coxon F; Middleton G; Daniel F; Oates J; Norman AR
J Clin Oncol; 2009 Aug; 27(23):3786-93. PubMed ID: 19398575
[TBL] [Abstract][Full Text] [Related]
20. Prospective, open, multicentre Phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and cisplatin for esophageal carcinoma.
Ma HB; Di ZL; Wen J; Ke Y; Sun X; Ren J
Jpn J Clin Oncol; 2015 Feb; 45(2):169-75. PubMed ID: 25416813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
